8-K: Pasithea Therapeutics Expands At-The-Market Offering Capacity to Over $4.2 Million

Pasithea Therapeutics Corp. announced an increase in the maximum aggregate offering price of its common stock under its At The Market Offering Agreement, raising it from $2,076,000 to $4,227,000.

Summary

• Pasithea Therapeutics Corp. increased the maximum aggregate offering price of its common stock under its At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC.
• The offering price was raised from $2,076,000 to $4,227,000.
• An additional $2,151,000 of common stock shares are now available to be sold under the Sales Agreement.
• Prior to this increase, the company had already sold approximately $2,075,688 worth of shares under the same agreement.
• A prospectus supplement was filed on June 20, 2025, to register these additional shares.

Sentiment

Score: 6

Explanation: The increase in capital raising capacity is generally positive as it provides financial flexibility and funding for operations. However, it also implies potential dilution for existing shareholders, balancing the overall sentiment to moderately positive.

Positives

• Increased capital raising capacity provides additional financial flexibility for the company.
• The At The Market offering mechanism allows the company to raise capital opportunistically based on market conditions.
• Secures funding for ongoing operations or future strategic initiatives without immediate large-scale dilution events.

Negatives

• The sale of additional common stock will result in dilution for existing shareholders.
• Potential downward pressure on the stock price as more shares become available in the market.

Risks

• Share Dilution: The issuance of additional common stock will dilute the ownership percentage of current shareholders.
• Market Price Volatility: The sale of shares under the ATM agreement could put downward pressure on the company's stock price, especially if a large volume of shares is sold over a short period.
• Uncertainty of Proceeds: The actual amount of capital raised will depend on market conditions and the company's ability to sell shares at favorable prices.

Future Outlook

The document indicates the company's intent to continue raising capital through its At The Market offering, suggesting a focus on securing funding for ongoing operations or future strategic initiatives. The legal opinion confirms the validity of the shares to be issued.

Management Comments

• The report was signed by Tiago Reis Marques, Chief Executive Officer, on behalf of Pasithea Therapeutics Corp.

Industry Context

This capital raise via an ATM offering is a common financing strategy for biotechnology and pharmaceutical companies, particularly those in development stages, to fund research and development, clinical trials, and general corporate purposes without the immediate pressure of a large, one-time equity offering. It provides flexibility to tap into the market as needed.

Stakeholder Impact

• Shareholders: Potential dilution of ownership and earnings per share due to the issuance of additional common stock.
• Company Operations: Enhanced financial flexibility to fund ongoing research, development, and general corporate purposes.

Next Steps

• Continued sale of common stock shares under the At The Market Offering Agreement up to the new maximum aggregate offering price of $4,227,000.

Key Dates

Recommendation

Keywords

Pasithea Therapeutics, KTTA, At The Market Offering, ATM, Common Stock, Equity Offering, Capital Raise, SEC Filing, Form 8-K, Prospectus Supplement, H.C. Wainwright & Co., Biotechnology, Pharmaceuticals